Bristol Myers Squibb's Iza-Bren cuts risk of progression or death by 59% in Phase 3 breast cancer trial

Bitget2026/10/23 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bristol Myers Squibb reported iza-bren outperformed chemotherapy in the Phase 3 PANKU-Breast01 breast cancer trial, reducing disease progression or death.
The trial enrolled patients with advanced HR-positive, HER2-negative breast cancer whose disease had progressed despite prior chemotherapy.
Safety was manageable, with no new safety signals identified; few patients discontinued treatment because of treatment-related adverse events.
Results will be presented at ESMO 2026, running October 23-27 in Madrid, with simultaneous publication in The Lancet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202610230730BIZWIRE_USPR_____20261022_BW086856) on October 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bristol Myers Squibb's Iza-Bren cuts risk of progression or death by 59% in Phase 3 breast cancer trial

You may also like

Crypto prices